NCT02574598View on ClinicalTrials.gov

MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

October 31, 2019

Study Completion Date

November 19, 2020

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

MK-3475

The dosing interval of pembrolizumab can be increased in case of toxicity.

DRUG

Docetaxel

Use on both arms as standard of care.

Trial Locations (1)

14080

National Cancer Institute of Mexico, Mexico City

All Listed Sponsors
lead

Instituto Nacional de Cancerologia de Mexico

OTHER

NCT02574598 - MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients | Biotech Hunter | Biotech Hunter